Continuing treatment with THIO plus cemiplimab (Libtayo) past 12 months “demonstrates safety, efficacy, and ongoing benefit” in patients with advanced non-small cell lung cancer (NSCLC) who experienced failure of 2 or more standard-of-care therapy regimens, according to an announcement from MAIA Biotechnology, Inc. THIO, which is 6-thio-dG or 6-thio-2’-deoxyguanosine, is a first-in-class investigational telomere-targeting agent. The regimen of THIO plus cemiplimab is under evaluation in the multicenter, open-label, dose-finding, phase 2 THIO-101 clinical trial, which is the first trial designed to evaluate the antitumor activity of THIO followed by PD-(L)1 ...
Lung Cancers Today
A new medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and more.
Advertisement
Study investigators say that extended follow-up research on nivolumab consolidation is essential.
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
Dr. Paz-Ares shares his insights on the study's results and the remaining questions about ADCs in lung cancer treatment.
The novel B7-H3–targeting antibody-drug conjugate has a novel payload.
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
A researcher discusses the implications of identifying potentially pathogenic bacteria in adenocarcinoma tumors.
The study showed that the detection of ctDNA predicted significantly inferior NSCLC.
Valsamo Anagnostou, MD, PhD, discusses advances in the field and her lab's research on the topic.
A new study showed surprising results about lung cancer screening during the pandemic.
The drug combination showed "reduced efficacy" in terms of PFS and OS, officials said.
Advertisement
Expert Interviews on Lung Cancer
Conference Coverage
Find the latest updates on lung cancer treatment and research from the 2024 ASCO Annual Meeting.
Our editors detail the latest data and innovations in the lung cancer space presented at ATS 2024.
Our editors deliver in-depth coverage of NACLC 2023, a premier event offering the latest data on lung cancer advancements.
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
